4.8 Article

New dextran coated activated carbons for medical use

Journal

CARBON
Volume 97, Issue -, Pages 134-146

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.carbon.2015.09.042

Keywords

-

Funding

  1. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme
  2. International Research Staff Exchange Scheme programme, project MEAD-ET [247547 FP7-PEOPLE-2009-IRSES]
  3. Industry-Academia Partnerships and Pathways project ACROBAT [286366 FP7-People-2011-IAPP]
  4. National Institute for Health Research [II-FS-0909-13116, II-LA-1111-20003] Funding Source: researchfish
  5. The British Council [GII110] Funding Source: researchfish
  6. National Institutes of Health Research (NIHR) [II-LA-1111-20003, II-FS-0909-13116] Funding Source: National Institutes of Health Research (NIHR)

Ask authors/readers for more resources

Activated carbon (AC) can be used for blood purification (hemoperfusion) to treat a range of conditions by direct perfusion of blood through an adsorbent column. The clinical effects of hemoperfusion relate to the AC adsorptive capacity, and any inflammatory response generated by direct blood contact. The use of a biocompatible coating minimizes side-effects but at the same time significantly reduces AC adsorption capacity in particular towards substances with large molecular mass. We investigated the adsorption capacity for biological molecules in a wide range of molecular masses and biocompatibility of a dextran (Dx) coated mesoporous AC (HSGD) produced from a polymer precursor. The hemocompatibility of the Dx-coated beads was investigated according to the ISO guidelines. Coating the HSGD with a Dx coating (5-30% weight of AC) decreased the specific surface area and pore volume of the materials and reduced adsorption capacity for methylene blue, vitamin B12, bilirubin and albumin, while minimizing fines production. Even the partially coated materials did not activate the inflammatory response and thus could be considered hemocompatible, with the Dx coating reducing fibrinogen adsorption and complement generation, suggesting the material warrants continued development for hemoperfusion applications. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available